of CMV. This translates to an absolute improvement in 1-year survival of 13%, 16% in MV and 29% in CMV. The median survival for CMV and MV was 7 months and 4.5 months respectively. Two hundred and eight patients objectively progressed or died. The hazard ratio was 0.55 (95% Cl 0.41-0.73, P-value = 0.0001) in favour of CMV. Two hundred and nine patients symptomatically progressed or died. The hazard ratio was 0.48 (950°o Cl 0.36-0.64. P-value = 0.0001) in favour of CMV. The most important pretreatment factors influencing overall survival were WHO performance status and extent of disease. These two factors were used to derive a prognostic index which could be used to categorize patients into three prognostic groups. We conclude that the addition of cisplatin to methotrexate and vinblastine should be considered in patients with transitional cell carcinoma, taking into account the increased toxicity.
). Hox-exer. response and surxival were generally short and no clear benefit for combination chemotherapy could be demonstrated. However. w ith the dex elopment of methotrexate -inblastine adriamv cin( doxorubicin) cisplatin (IM-VAC) (Sternberg et al 1985 (Sternberg et al . 1988 (Sternberg et al . 1989 ). a drug combination incorporating all these drugs. and CMV (omittinc doxorubicin: Hark-er et al. 1985 : Jeffern et al. 1992 ). large improvements in remission rate were reported in single-institution studies. with reports of longterm sunrival in 20'c of patients in one study (Sternberg et al. 1989) . In a subsequent randomized trial. howex er. comparing single-agent cisplatin wxith M-VAC (Loehrer et al. 1992) . the essentially palliative nature of these treatments w as demonstrated.
W'hile M-VAC proxed capable of increasing median sun-ix al time from 8 months to 12 months. a 5-y ear progression-free surnival of only 4%/c wxas reported (Saxman et al. 1997) . Similarlx. in a large retrospective study of patients receix ing cisplatin combination chemotherapy for locally adx anced or metastatic urothelial cancer Fossa et al. 19961 . a 5-xear survival rate of only 11 'k wxas reported. M-VAC has also been reported to improx e surnixval wxhen compared with CISCA (cisplatin. cyclophosphamide and doxorubicin) in a randomized trial (Logothetis et al. 1990 ).
Combination chemotherapy including, cisplatin is toxic. resulting in marked morbidity-for the majority of patients and treatment-related mortality in up to 4%,c of cases (Loehrer et al. 1992 ). Cisplatin itself is probably responsible for most of the impairment of quality of life. and the precise role of this drug in the management of these cancers has not been clearlv demonstrated. Cisplatin-based treatment can also be inconvenient to the patient. usually requirinc hospitalization for administration. In the trial comparing single-agent cisplatin with M-VAC (Loehrer et al. 1992) . an overall response rate of only 12%7c A-as described for cisplatin used as a single agent.
In 1991. the British MIedical Research Council initiated a trial comparing, combination chemotherapy with CMV (cisplatin gix en at a dose of 70 mg, m-' ) with a modified methotrexate and X inblastine (MV) regrimen. This latter regimen can be gaixen on an outpatient basis and was reported as providing a 40%7c response rate (complete response plus partial response) in metastatic transitional cell cancer when used on a weekly basis (Ahmed et al. 1985) . This trial was designed to ex aluate the impact of cisplatin on this disease.
PATIENTS AND METHODS Study design and randomization
Patients eligible for this study had to have a histologically confirmed diarnosis of transitional cell carcinoma arising at any site in the urothelial tracts. Patients with mixed tumours (i.e. tumours containing elements of squamous cell or adenocarcinoma) were also eligible for inclusion in this studv. although patients '-ith pure non-TCC tumours w-ere excluded. Patients should have been considered incurable by surgery or radiotherapy and the follow-ing groups were included: (1) metastatic disease at anv site (includinc completely resected pelvic nodal disease). (2) invasive pelvic relapse after radical radiotherapy and (3) initial presentation '-ith T4b disease. It A as not considered essential that patients had measurable disease. as the primary end point of the study A as length of sun-ival.
Further elicribilitv criteria wxere as follows: all patients were required to have a nonnal blood count (WBC > 3.5 x l0 1-1 with a platelet count > 100 x 109 1-1) and a glomerular filtration rate (GFR). calculated bh the method of Cockcroft and Gault ( 1976) absolute benefit to CMV w-as less than 10-15%7c. To exclude an absolute improvement larger than 15% (that is. say. from 20% in the CMV arm to 5% or less in the MV arm) required that 200 patients Awere randomized (significance lexel = 10%. pow er = 90%c). Randomization of 400 patients would allow us to exclude a difference of 10%c with the same significance lexel and power. It was decided to aim for 200 patients in the first instance and. if adequate accrual was attained. the trial would continue to enter 400 patients.
Treatments
All patients w'ere planned to receive six cxcles of either MV or CMV. Patients 'Aere re-exaluated after txo treatment cycles: if treatment-related symptoms were stable. or improxed and simple re-evaluation (physical examination. lixer function tests. chest radiography and abdominal and/or pelvic ultrasound) showed no evidence of disease progression. treatment was continued. in the absence of disease progression. for six cycles.
Both regimens. MV and CMV. were gix en over a 21-day cycle. MV compn'sed methotrexate at 30 mg m-given by slowx intraxvenous push on days 1 and 8 and vinblastine at 4 mc m-' gixen by intraxenous push on days 1 and 8. Folinic acid rescue wxas gixen 24 h after each methotrexate injection at a dose of 15 mg orally. 6-hourly x 4. CMV comprised MV gixven exactly as described. but included, in addition. inpatient administration of cisplatin at a dose of 70 mg m-on day 2. Cisplatin was given following a period of i.x. hvdration in which at least 2 1 of normal saline was ixven. and '-as not administered until urine output A as measured as equalling or exceeding 100 ml h-I for 4 h. Cisplatin A-as administered in 500 ml of normal saline over 1 h and was followed bv at least ' 1 further hydration with normal saline. with supplementary potassium chloride and magnesium sulphate.
All three chemotherapy drugs were gix en at full dose. on time. if the white blood count was > 3.5 x 109 1-1 with a platelet count of > l0Ox 10x1-1 and calculated GFR was >S0ml min-'. Methotrexate and xinblastine doses wAere reduced bx 25%7c for WBC 3-3.5 x 109 1-1 and bv 50% for WBC 2.5-2.9 x 10' 1-1. A WBC of < 2.5 x 109 1-1 or platelets < 100 x 104 1-' on day 1 caused delay of chemotherapy by up to 2 weeks: on day 8. chemotherapy was omitted if these counts were found. A GFR of 35-50 ml on day 2 resulted in a reduction of cisplatin dose by 50%'c. Methotrexate and cisplatin wAere omitted if the GFR Awas <35 ml mnn. or radiolouicallv) and ox erall sur ix al were measured from the date of randomization. Survival and progression-free sunrival cunres were formed by the Kaplan-Meier method and compared using the Mantel-Cox xversion of the log-rank test. To assess whether CMV or MV wxere more or less effective in well-defined subgroups. a X' test for heterogeneity or. when appropriate. trend wxas performed. All analyses were performed on an intention-totreat basis. all tests are from a X' distribution with one degree of freedom and all P-xvalues are two-sided unless otherwise specified (Parmar and Machin. 1995) . The statistical methods used were implemented using SAS (1989) .
Absolute benefits at specific time points for CMV for overall survival were calculated using the Kaplan-Meier estimate for survival on the MV arm at that time point (baseline sunrival). using the expression: absolute benefit = exp (hazard ratio x log baseline) -baseline sun-ix al. This approach wxas also adopted for the end points of objective and symptomatic progression-free survival. Although this approach implicitly assumes proportional hazards. it is preferable to reading off differences between the Kaplan-Meier curnes at indix idual time points (Parmar and Machin. 1995 Analvsis of prognostic factors was done by using, the Cox proportional hazards model. To build a model. unix ariate analyses were done usinc a P-alue of 0.10 to determine whether to include a variable in the overall model. A forward selection procedure w as used to build a model and a prognostic index wxas developed. The methods used in this whole process are described in Parmar and Machin (1995) .
RESULTS
From April 1991 to June 1995. 214 patients were entered into this multi-institution study from a total of 16 centres within the UK.
Entrv bx institution is showxn in Table 1 and patient characteristics are shown in Table 2 . The patients were well matched with regard to these patient characteristics in the two treatment groups.
Treatment delivery and response
One hundred and eight patients were randomized to receive combination chemotherapy with CMV and 106 patients were randomized to receixe MV chemotherapy (Table 3) Long-term toxicitv (neurological) was reported in nine CMV patients and one patient on MV (although this patient actually received CMV). (visceral. non-visceral) give useful independent information on the likely survival of patients. Table 6 shows the final Cox model with the estimates of the regression coefficients. To simplify the model. we attempted to develop a prognostic index. The prognostic index (PI) is used to derive a score from the key patient characteristics of WHO and extent of disease. which can then be used to indicate whether a patient has a good. intermediate or poor prognosis.
Effects in different subgroups
To derive a PI. it is usual to simplify the regression coefficients in the fitted Cox model. The exponent part of the fitted Cox model is 0.411W + 0.545E: preserving the ratio of the coefficients. 0.411:0.545 can be simplified to 3:4. giving PI = 3W + 4E (hence the index scores in Table 6 ).
The PI can be calculated for each patient. which gives a range from 0 to 10. a high score of PI indicating a poorer prognosis and a low score a better prognosis. The distribution of PI was examined and convenient subgroups of prognosis were identified. The goodprognosis group were defined as having a PI < 4: this group of patients includes those with WHO 0 or 1 and non-visceral disease. (Fossa et al. 1996) .
Britsh Joumal of Cancer (1998) 78(8) (Loehrer et al. 1994 ) and the MD Anderson study of M-VAC vs CISCA (Logothetis et al. 1990 ). There are a number of possible explanations for this. We deliberately chose to be as inclusive as possible in our study to represent as nearly as possible the true nature of this patient population. In this regard. we accepted patients with a relatively low GFR (greater than 50 ml min-') and used a lower dose of cisplatin than used in the original CMV regimen (70 mg m-' vs 100 mg m-: Harker et al. 1986 ). although there is no good evidence to suggest that this latter approach may be disadvantageous. Approximatelv 50% of our patients had received previous radiation compared with 25-30% in most series derived from the US. We deliberately included patients with non-measurable disease. a common situation following pelvic radiation which may be associated with an adverse outlook (Jeffery et al. 1992 ).
The study adequately highlighted the beneficial effect of cisplatin. increasing the median surnival from 4.5 to 7.5 months and the -year survival from 16%7 to 29%. Improvements were also seen in symptomatic and objective progression-free sun ival. However. the toxicity of CMV and the relative inefficacy of both these regimens was highlighted both by the low proportion of patients completing the planned six cycles of chemotherapy and by the high proportion of patients discontinuing chemotherapy because of disease progression or excessive toxicity. We. like other inxestigators (Tannock et al. 1989) . conclude from this study that the drugs incorporated in CMV (or M-VAC). while achiex ing short-term disease regression. on the whole British Jourmal of Cancer (1998) 78(8) pro'ide poor palliation for a majority of patients. A number of studies have attempted to increase the dose intensity of M-VAC by simultaneous administration of orowth factors (Loehrer et al. 1994 : Logothetis et al. 1985 . The majoritv of these studies have concluded that this resulted in a modest increase in dose intensitv.
with markedlv increased toxicity with no obvious clinical benefits.
However. the European Organization for Research and Treatment of Cancer. following a successful randomized phase II trial in which no increase in toxicity was seen (Sternbera et al. 1997) . is currently randomizing patients in a phase III trial between M-VAC and accelerated M-VAC supported by growth factors.
A number of new drugs and drug combinations are now under early staaes of evaluation by ourselves and others. These agents include the taxanes. paclitaxel (Roth et al. 1994 ) and docetaxel (McCaffrey et al. 1995) . g!emcitabine (Stadler et al. 1995) ifosfamide (Witte et al. 1997 ) and gallium (Seligman et al. 1991 New prospective studies should therefore examine not only response rates and survival. but also quality of life to assess the true impact of therapies. which are often toxic. on this patient population.
In summarv. this randomized trial demonstrated a clear improvement in symptomatic and objective pro-ression-free survival. together with survival as a result of the addition of cisplatin to methotrexate and vinblastine. This improvement in anti-cancer effect was. however. achieved at the cost of increased toxicity. Cisplatin containing combinations can be recommended for patients in whom benefit is likely to exceed toxicity. New-treatment approaches should be supported and evaluated in randomized clinical tnials.
